After twice insisting that the drug mifamurtide was too costly and that supporting evidence for it was too small, the clinical-effectiveness agency for England and Wales says that it will recommend the drug to treat a rare form of bone cancer affecting people younger than age 30. The National Institute for Health and Clinical Excellence (NICE) said in final draft guidance Sept. 7 that its decision came as a result of both mifamurtide's manufacturer offering additional discounts, and a fresh cost...